News and press
Focus successful in UK litigation against Novartis concerning Voleze® Rivastigmine Transdermal Patches
Company performance and financials
Focus has grown significantly since it was started as shown by the financials below.
The Company continues to invest approximately 50% of expenditure in new product development projects. This continued investment in the pipeline, and a fairly consistent overhead base means that almost all new product profits increase the operating profit directly.